Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Ut commodo pretium nisl. Integer sit amet lectus. Nam suscipit magna nec nunc. Maecenas eros ipsum, malesuada at, malesuada a, ultricies dignissim, justo. Mauris gravida dui eget elit. In lacus est, bibendum vitae, malesuada quis, lacinia vel, nulla. Aenean varius mauris vitae neque. Maecenas a nibh. Curabitur pretium tortor. Integer nec dolor non ante semper tincidunt. Cras consectetuer mauris vel quam. Morbi tincidunt, urna sed varius pellentesque, ligula justo blandit quam, sed tempus purus mauris sit amet dui. In sapien mauris, eleifend id, malesuada sed, faucibus nec, elit. Quisque facilisis faucibus neque. Sed malesuada mi eget elit. Fusce mauris massa, posuere a, sodales sit amet, egestas id, elit.

Für weitere Informationen kontaktieren Sie bitte

Deutsche Biotech Innovativ AG
Frau Susanne Wallace
Tel.: +49 (0)3302 20 77 811
E-Mail: s.wallace@dbi-ag.de

Kirchhoff Consult AG
Frau Anja Ben Lekahl
Tel.: +49 (0)40 609 186 55
E-mail: anja.benlekhal@kirchhoff.de

veröffentlicht unter:

http://www.dgap.de/dgap/News/corporate/deutsche-biotech-innovativ-sepsiswirkstoff-adrecizumab-zeigt-hohe-wirksamkeit-praeklinik/?newsID=891875&companyID=363635

Attachments

  • Original document
  • Permalink

Disclaimer

Deutsche Biotech Innovativ AG published this content on 16 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 September 2020 09:09:06 UTC